康諾亞－Ｂ
Building D2
No. 18 BioTown Middle Road Tianfu International BioTown Shuangliu District
Chengdu 610219
China
86 28 8861 0620
https://www.keymedbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 897
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Bo Chen | Executive Chairman & CEO | 4.44M | 無 | 1975 |
| Dr. Gang Xu | Senior VP & Executive Director | 1.49M | 無 | 1975 |
| Dr. Changyun Wang | Senior VP & Executive Director | 2.44M | 無 | 1966 |
| Mr. Qi Chen | Senior VP & Non Executive Director | 691.16k | 無 | 1975 |
| Mr. Yanrong Zhang | CFO & Joint Company Secretary | 無 | 無 | 1989 |
| Dr. Qian Jia | Senior Vice President | 無 | 無 | 1966 |
| Ms. Pak Yu Tam A.C.I.S., A.C.S. | Joint Company Secretary | 無 | 無 | 無 |
描述
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
公司管治
截至 無 止，康諾亞－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
